Investing in Medicine
Aescap Life Sciences is a biotech fund that invests in publicly traded biotech companies. It invests in high-growth, highly innovative companies that develop and market new medicines and, to a lesser extent, diagnostics and/or medical devices. Aescap Life Sciences has around 200 million euros under management and has an annualized net performance of around 16% over its five years of existence. Entry into and exit from this biotech fund is possible twice per month.
The biotech market is a large and fast-growing market. The substantial growth of the biotech market, also called life sciences market, is driven by an ageing population and an increased demand for ‘Western’ medicine in the emerging markets. After 30 years of development, groundbreaking technologies such as RNA, gene and cell therapies come to the market which often allow for more effective and safer medicines. These factors together are driving demand for improved and cost-effective medicine, diagnostics and medical devices. Since there are more than 1.000 public biotech companies, it is difficult to select those that will beat their competitors in the future. With over 30 years of experience investing in the life sciences market, Aescap Life Sciences enables investors to invest into the future winners of this industry. An investment in the fund will not only generate a good return on investment, it also supports the development of better treatments for diseases with a high unmet medical need such as ALS, Alzheimer’s, Arthritis, Cancer, MS, Obesity, Parkinson’s and many others.